Callio Therapeutics Debuts with $187M to Develop Next-Generation Multi-Payload ADCs for Cancer

Callio Therapeutics launches with $187M Series A to develop multi-payload ADCs

Key facts:

• Callio Therapeutics launched with a $187 million Series A financing round led by Frazier Life Sciences123

• The company has headquarters in Seattle and Singapore14

• Callio licensed Hummingbird Bioscience's multi-payload ADC platform and pipeline assets in exchange for equity, potential milestones and royalties13

• Funding will advance clinical proof-of-concept for a HER2-targeted dual-payload ADC and a second undisclosed ADC program13

• CEO Piers Ingram was previously CEO of Hummingbird Bioscience510

• Other investors include Jeito Capital, Novo Holdings, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI13

Sources:

1. https://www.biospectrumasia.com/news/26/25671/callio-therapeutics-launches-with-187-m-series-a-round-to-advance-multi-payload-adc-platform.html

2. https://european-biotechnology.com/latest-news/adc-maker-callio-therapeutics-secures-us187m-in-series-a-round/

3. https://pharmasource.global/content/biotech-news/callio-therapeutics-launches-with-187m-to-develop-next-gen-adc-cancer-therapies/

4. https://novoholdings.dk/news/novo-holdings-participates-in-187-million-series-a-launch-financing-for-callio-therapeutics-to-advance-innovative-dual-payload-adc-programs-in-oncology

5. https://endpts.com/callio-emerges-with-187m-and-adcs-from-a-decade-old-singapore-biotech/

10. https://www.fiercebiotech.com/biotech/frazier-arms-callio-187m-series-fly-hummingbirds-her2-dual-adc-clinic